These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 9541334)

  • 81. No association of a set of candidate genes on haloperidol side effects.
    Drago A; Giegling I; Schäfer M; Hartmann AM; Möller HJ; De Ronchi D; Stassen HH; Serretti A; Rujescu D
    PLoS One; 2012; 7(10):e44853. PubMed ID: 23077486
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Poor response to treatment: beyond medication.
    Carvajal C
    Dialogues Clin Neurosci; 2004 Mar; 6(1):93-103. PubMed ID: 22034452
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Social interaction and drug attitude effectiveness in patients with schizophrenia.
    Tsai JK; Lin WK; Lung FW
    Psychiatr Q; 2011 Dec; 82(4):343-51. PubMed ID: 21499787
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Clinical outcomes of long-acting injectable risperidone in patients with schizophrenia: six-month follow-up from the Electronic Schizophrenia Treatment Adherence Registry in Latin America.
    Apiquian R; Córdoba R; Louzã M
    Neuropsychiatr Dis Treat; 2010 Dec; 7():19-26. PubMed ID: 21326651
    [TBL] [Abstract][Full Text] [Related]  

  • 85. A rapid method for creating drug implants: translating laboratory-based methods into a scalable manufacturing process.
    Wang CK; Wang WY; Meyer RF; Liang Y; Winey KI; Siegel SJ
    J Biomed Mater Res B Appl Biomater; 2010 May; 93(2):562-72. PubMed ID: 20225251
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Costs of new atypical antipsychotic agents for schizophrenia: does unrestricted access reduce hospital utilization?
    O'Reilly D; Craig D; Phillips L; Goeree R; Tarride JE; Parfrey P
    Healthc Policy; 2007 Aug; 3(1):58-79. PubMed ID: 19305756
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Subjective reasons for adherence to psychotropic medication and associated factors among older adults with schizophrenia.
    Sapra M; Vahia IV; Reyes PN; Ramirez P; Cohen CI
    Schizophr Res; 2008 Dec; 106(2-3):348-55. PubMed ID: 18851906
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Tactics and technologies to manage nonadherence in patients with schizophrenia.
    Glazer WM; Byerly MJ
    Curr Psychiatry Rep; 2008 Aug; 10(4):359-69. PubMed ID: 18627676
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Religious beliefs in schizophrenia: their relevance for adherence to treatment.
    Borras L; Mohr S; Brandt PY; Gilliéron C; Eytan A; Huguelet P
    Schizophr Bull; 2007 Sep; 33(5):1238-46. PubMed ID: 17213479
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Family support predicts psychiatric medication usage among Mexican American individuals with schizophrenia.
    Ramírez García JI; Chang CL; Young JS; López SR; Jenkins JH
    Soc Psychiatry Psychiatr Epidemiol; 2006 Aug; 41(8):624-31. PubMed ID: 16733631
    [TBL] [Abstract][Full Text] [Related]  

  • 91. The impact of subjective well-being under neuroleptic treatment on compliance and remission.
    de Millas W; Lambert M; Naber D
    Dialogues Clin Neurosci; 2006; 8(1):131-6. PubMed ID: 16640124
    [TBL] [Abstract][Full Text] [Related]  

  • 92. A study of treatment outcomes from atypical antipsychotic medications in the Virginia public system of community care.
    Ziegler DM; Peachey TJ
    Community Ment Health J; 2003 Apr; 39(2):169-82. PubMed ID: 12723850
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Olanzapine: an updated review of its use in the management of schizophrenia.
    Bhana N; Foster RH; Olney R; Plosker GL
    Drugs; 2001; 61(1):111-61. PubMed ID: 11217867
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Patient compliance with drug therapy in schizophrenia. Economic and clinical issues.
    Lindström E; Bingefors K
    Pharmacoeconomics; 2000 Aug; 18(2):106-24. PubMed ID: 11067646
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Development of an integrated cognitive-behavioral and social skills training intervention for older patients with schizophrenia.
    McQuaid JR; Granholm E; McClure FS; Roepke S; Pedrelli P; Patterson TL; Jeste DV
    J Psychother Pract Res; 2000; 9(3):149-56. PubMed ID: 10896740
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Measuring neuropsychological change in schizophrenia with novel antipsychotic medications.
    Purdon SE
    J Psychiatry Neurosci; 2000 Mar; 25(2):108-16. PubMed ID: 10740984
    [No Abstract]   [Full Text] [Related]  

  • 97. Facilitating compliance with antipsychotic medication.
    Marder SR
    J Clin Psychiatry; 1998; 59 Suppl 3():21-5. PubMed ID: 9541334
    [TBL] [Abstract][Full Text] [Related]  

  • 98. A double-blind study of combination of clozapine with risperidone in patients with schizophrenia: effects on cognition.
    Akdede BB; Anil Yağcioğlu AE; Alptekin K; Turgut TI; Tümüklü M; Yazici MK; Jayathilake K; Tunca Z; Göğüş A; Meltzer HY
    J Clin Psychiatry; 2006 Dec; 67(12):1912-9. PubMed ID: 17194269
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Novel pharmacological approaches to the treatment of schizophrenia.
    Fink-Jensen A
    Dan Med Bull; 2000 Jun; 47(3):151-67. PubMed ID: 10913983
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Cognitive and psychomotor effects of risperidone in schizophrenia and schizoaffective disorder.
    Houthoofd SA; Morrens M; Sabbe BG
    Clin Ther; 2008 Sep; 30(9):1565-89. PubMed ID: 18840365
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.